BioSpace News Archive

Biotech Bay

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 22, 2024

Ultragenyx Pharmaceutical Inc. reported the grant of 13,020 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company.

March 22, 2024
·
1 min read
Business

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

Inventiva (Euronext Paris and Nasdaq: IVA) today announced that its management team will host a webcast to present the Company’s 2023 full-year financial results on Thursday, March 28, 2024.

March 22, 2024
·
3 min read
BioMidwest

Veru Reschedules Annual Meeting of Shareholders - March 22, 2024

Veru Inc. announced that it is rescheduling its 2024 Annual Meeting of Shareholders originally scheduled to be held on March 26, 2024.

March 22, 2024
·
7 min read
Biotech Beach

Masimo Corporation Board of Directors Authorizes Management to Evaluate the Separation of Consumer Business

Masimo, a global leader in noninvasive monitoring technologies and audio products, announced that its Board of Directors has authorized management to evaluate a proposed separation of its consumer business.

March 22, 2024
·
8 min read
Alvotech Announces Increase in Number of Own Shares

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and thirty thousand by issuing thirteen million ordinary shares.

March 22, 2024
·
2 min read
Business

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and twelve months ended December 31, 2023 financial results.

March 22, 2024
·
8 min read
Lone Star Bio

Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB

Castle Biosciences, Inc. announced that new data highlighting the performance of its DecisionDx-Melanoma test in predicting risk of sentinel lymph node positivity in patients with CM is being presented at the Society of Surgical Oncology 2024 Annual Meeting, being held March 20-23 in Atlanta.

March 22, 2024
·
7 min read
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

NLS Pharmaceutics Ltd. announced the closing of its previously announced registered direct offering of 7,000,000 of its common shares at a purchase price of $0.25 per share.

March 22, 2024
·
5 min read
FDA

FDA Roundup: March 22, 2024

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

March 22, 2024
·
4 min read
Drug Development

In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN

NurExone Biologic Inc., a pioneering biopharmaceutical company, developing regenerative medicine therapies, is proud to announce a strategic service agreement with Vivox Ltd., a leading provider of animal testing and services in Israel to biotech and pharmaceutical companies.

March 22, 2024
·
7 min read